Oncology Supportive Care Testing
Prediction of neurological side effects from oncology drugs
PreclinicalActive
Key Facts
Indication
Prediction of neurological side effects from oncology drugs
Phase
Preclinical
Status
Active
Company
About 28Bio
28Bio is a private, preclinical-stage biotech leveraging its proprietary Nexon™ platform to create engineered human brain and peripheral nervous system organoids for neurotoxicity and efficacy testing. The company's technology, which combines 3D tissue engineering, embedded neural electrodes, and AI-driven analysis, has demonstrated superior predictive performance compared to animal models, as evidenced by its retrospective Endurance Study. 28Bio operates primarily as a platform and services company, offering predictive assays to pharmaceutical partners to de-risk neurological drug development, and is currently in a pre-revenue stage.
View full company profile